MEIS1, PREP1, and PBX4 Are Differentially Expressed in Acute Lymphoblastic Leukemia: Association of MEIS1 Expression with Higher Proliferation and Chemotherapy Resistance by Rosales-Aviña, Judith A et al.
RESEARCH Open Access
MEIS1, PREP1, and PBX4 Are Differentially
Expressed in Acute Lymphoblastic Leukemia:
Association of MEIS1 Expression with Higher
Proliferation and Chemotherapy Resistance
Judith A Rosales-Aviña
1†, Jorge Torres-Flores
1†, Adriana Aguilar-Lemarroy
1, Carmen Gurrola-Díaz
2,
Georgina Hernández-Flores
1, Pablo C Ortiz-Lazareno
1, José M Lerma-Díaz
1, Ruth de Celis
1,
Óscar González-Ramella
3, Esperanza Barrera-Chaires
4, Alejandro Bravo-Cuellar
1 and Luis F Jave-Suárez
1*
Abstract
Background: The Three-amino acid-loop-extension (TALE) superfamily of homeodomain-containing transcription
factors have been implicated in normal hematopoiesis and in leukemogenesis and are important survival,
differentiation, and apoptosis pathway modulators. In this work, we determined the expression levels of TALE genes
in leukemic-derived cell lines, in blood samples of patients with Acute lymphoblastic leukemia (ALL), and in the
blood samples of healthy donors.
Results: Here we show increased expression of MEIS1, MEIS2, and PREP1 genes in leukemia-derived cell lines
compared with blood normal cells. High levels of MEIS1 and PREP1, and low levels of PBX4 expression were also
founded in samples of patients with ALL. Importantly, silencing of MEIS1 decreases the proliferation of leukemia-
derived cells but increases their survival after etoposide treatment. Etoposide-induced apoptosis induces down-
regulation of MEIS1 expression or PREP1 up-regulation in chemotherapy-resistant cells.
Conclusions: Our results indicate that up-regulation of MEIS1 is important for sustaining proliferation of leukemic
cells and that down-regulation of MEIS1 or up-regulation of PREP1 and PBX genes could be implicated in the
modulation of the cellular response to chemotherapeutic-induced apoptosis.
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Background
Three-amino-acid loop extension (TALE) genes belong to
the homeobox group and are distinguished by the pre-
sence of three extra amino acids in the loop binding the
first to the second alpha helix of the homeodomain [1].
TALE proteins include subfamilies MEINOX and PBC.
MEINOX is composed of the members MEIS1, MEIS2,
the recently described MEIS3, PREP1, and PREP2 in
humans [1,2]. The PBC subfamily contains PBX1, PBX2,
PBX3, and PBX4 proteins [3,4]. Expression of TALE genes
has been related with normal development, differentiation,
survival, apoptosis, and with the hematopoietic process
[5-10]. Indeed, some TALE genes are targets for viral
insertion or for chromosome translocations during leuke-
mogenesis. In this regard, MEIS1 has been characterized
as a common proviral integration site in BXH-2 mice [11];
in these mice, leukemic tumors that contain a viral inte-
gration site at the MEIS1 locus frequently possess an addi-
tional co-integration site in some HOX genes [12], which
suggests the required cooperative effect of MEIS and HOX
during leukemogenesis. Over-expression of MEIS1 in
CD34
+ hematopoietic cells has been related with suppres-
sion of differentiation, promotion of proliferation, and
self-renewal. Interestingly, high levels of MEIS1 in myeloid
progenitors have been shown to regulate the cellular
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ferentiation. Moreover, in the murine myeloid cell line
32Dcl3, it has been observed that MEIS1 can block granu-
locytic differentiation in response to G-CSF [13]. MEIS1
has been also found over-expressed in human leukemic
cells [14].
Other TALE proteins that have been also related with
normal hematopoiesis and leukemogenesis comprise
members of the PBX group. PBX proteins were first iden-
tified as HOX cofactors involved in developmental gene
regulation [15,16]. PBX1 plays a role in the development
of blood cell populations because hematopoietic stem cells
from PBX1-/- embryos have reduced colony-forming
activity and are unable to establish multilineage hemato-
poiesis in competitive reconstitution experiments [8].
PBX-PREP1 complexes are required for the production of
normal CD4 and CD8 T-lymphocytes. Furthermore, PBX-
MEIS complexes have been implicated in megakaryocyte
differentiation, and PBX-PREP complexes have been also
connected with the regulation of Interleukin (IL)-10 pro-
duction in macrophages during the phagocytosis of apop-
totic cells [17]. PREP proteins are also important during
development; for instance, deletion of PREP1 in mice and
zebrafish induces embryonic lethality [18,19]. Mice hypo-
morphic for PREP1 exhibit defects in T-cell development,
with a decreased number of single-positive thymocytes,
increased apoptosis of double-positive thymocytes, and
abnormalities in the expression of ab and gδ T-cell recep-
tors [19]. Additionally, reduction in PREP1 expression
directly affects the expression of MEIS and PBX and con-
sequently, normal embryonic hematopoiesis [20].
In summary, TALE genes codify for important tran-
scription factors involved in hematopoiesis and leukemo-
genesis and are important survival, differentiation, and
apoptosis pathway modulators in hematopoietic cells. In
this study, we analyzed the expression of TALE genes in
leukemia-derived cell lines, in samples of patients with
Acute lymphoblastic leukemia (ALL), and in samples of
clinically healthy donors. We observed consistent up-reg-
ulation of MEIS1 and PREP1 and down-regulation of
PBX4 in leukemic cell lines and in the samples of patients
with ALL. Interestingly, RNA-mediated down-modula-
tion of MEIS1 lowers leukemic cell proliferation. Addi-
tionally, chemotherapeutic treatment of lymphoblastic
cell lines induces an increment in PREP1, PBX2, and
PBX4 messenger RNA (mRNA) levels that could be
related with a more resistant phenotype.
Results
Higher Expression Levels of MEIS1, MEIS2, and PREP1
Genes in Leukemia-derived Cell Lines Compared with
Normal Cells
TALE genes are normally involved in the differentiation
of hematopoietic cells and their expression has been
related with deregulated differentiation. From this start-
ing point, we wanted to determine the expression levels
of TALE genes in cells with impaired differentiation. For
this purpose, we choose leukemic-derived cell lines and
normal differentiated cells as the study model. In order
to analyze the expression of TALE genes, we first
selected primer pairs to amplify these genes and proved
these primers by conventional PCR reactions utilizing a
pull of complementary DNA (cDNA) obtained from leu-
kemia-derived cell lines (Table 1). All primer pairs were
able to amplify a specific product corresponding to the
expected size for each TALE gene (Figure 1A); however,
for PBX1, we observed an additional band of lower
molecular size. We carried out the same approach to
analyze primer pairs designed to amplify the L32 riboso-
mal protein (RPL32) and Beta-Actin (ACTB)i no r d e rt o
have reference genes to measure relative gene expres-
sion (Figure 1A). Regarding PBX1, we also noticed the
Table 1 Primer pairs used for PCR reactions
GENE ACCESION
NUMBER
PRIMER SEQUENCE Tm
MEIS1 [GenBank:
NM_002398]
F: CCC CAG CAC AGG TGA CGA
TGA T
R: TGC CCA TTC CAC TCA TAG GTC
C
60
MEIS2 [GenBank:
NM_170677]
F: CCA TCG ACC TCG TCA TTG AT
R: CCT CCT TTC TTC TGG CGT TTT
T
60
PREP1 [GenBank:
NM_004571]
F: GGT TTT GGC CTG ATT CTA TTG
C
R: GTG GGG AGG GAG TGG TG
65
PREP2 [GenBank:
NM_022062]
F: GCC ACC AAT ATA ATG CGT TCT
T
R: GTG TTC CAA GCC CAG GTC
65
PBX1 [GenBank:
NM_002585]
F: CTA ACT CGC CCT CAA CTC C
R: GTG TCC AGA TTG GCT GAA
ATA G
60
PBX2 [GenBank:
NM_002586]
F: GGC GGC TCT TTC AAT CTC TCA
R: GTC TCG TTA GGG AGG GGA
TGA C
65
PBX3 [GenBank:
NM_006195]
F: CAA GGG TCC CAA GTC GG
R: TGG CCT AAT TGG ATA AAG
TGC T
60
PBX4 [GenBank:
NM_025245]
F: ATG GGG AAG TTT CAA GAA
GAG G
R: ATC TCG AGT CGC AGC AGA C
65
GAPDH [GenBank:
NM_002046]
F: CAC TGC CAC CCA GAA GAC
TGT G
R: TGT AGG CCA TGA GGT CCA
CCA C
60
RPL32 [GenBank:
NM_000994]
F: GCA TTG ACA ACA GGG TTC
GTA G
R: ATT TAA ACA GAA AAC GTG
CAC A
60
ACTB [GenBank:
NM_001101]
F: TCC GCA AAG ACC TGT ACG
R: AAG AAA GGG TGT AAC GCA
ACT A
60
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Page 2 of 12low-molecular-weight band existing in controls and in
all leukemia derived cell lines (Figure 1B). By sequence
analysis, we found that this corresponds to an isoform
of PBX1 in which exon 7 is lost (Figures 1B and 1C).
This indicated that our PCR primers were specific for
PBX1, and also that they are able to amplify both PBX1
versions. Because we planned to quantify gene expres-
sion by real time PCR (qRT-PCR) utilizing the SYBR
Green strategy, in the case of PBX1,t h ev a l u eo b t a i n e d
in quantification correspondt ot h es u mo ft h ee x p r e s -
sion of both isoforms.
Next, we proceeded to analyze the expression of TALE
genes by qRT-PCR in leukemia-derived cell lines. We
employed five cell lines including Jurkat, CEM, MOLT-
4, K562, and HL-60; the first three are lymphoblastic,
and the latter two, myeloid. We determined the crossing
point for each target gene and subsequently normalized
this with the crossing point of an internal reference
gene to calculate the ΔCP, which represents an absolute
and more comparative value (see Materials and Meth-
ods). It is important to bear in mind that the ΔCP value
is inversely proportional to gene expression. To obtain
more consistent results, we use two different reference
genes: RPL32,a n dACTB. As can be observed in Figure
2, results obtained with RPL32 and ACTB follow the
same tendency. In this regard, RPL32 and ACTB were
selected as confident reference genes. Interestingly,
when expression levels of TALE genes in leukemic cell
lines and blood-derived normal cells were evaluated, sig-
nificant differences were observed in the expression of
MEIS1, MEIS2, and PREP1. Normal blood cells have
greater ΔCP values for these three genes, thus lower
expression (Figure 2). For PREP2 and all PBX members,
we did not observe any variation. Additionally, on com-
paring ΔCP values we could note that in all cell lines
and control cells, PREP2 possesses the lowest mRNA
level.
Up-regulation of MEIS1 and PREP1 and Down-regulation
of PBX4 in ALL Samples vs. Those of Healthy Individuals
To confirm whether variations in TALE expression
observed in cell lines were also observed in samples of
patients with leukemia, we recruited 14 samples of
patients diagnosed with Acute lymphoblastic leukemia
(ALL) and 19 samples from clinically healthy volunteers
(Table 2). We again analyzed the genetic expression of
TALE genes by qRT-PCR employing the previously
mentioned RPL32 and ACTB as reference genes to
Figure 1 Analysis of primers used for amplification of Three-amino-acid loop-extension (TALE) family member genes. A) A pull of cDNA
obtained from leukemia-derived cell lines was utilized to test the specificity and efficiency of each set of primers in the amplification of TALE
family genes. After 40 cycles of amplification by conventional PCR, the PCR products were separated into 2% agarose gels and visualized under
Ultraviolet (UV) light. Amplification products of the reference genes employed (RPL32 and ACTB) are also included. The 1 Kb Plus DNA Ladder
(Invitrogen, Life Science) is shown in the left line; B) Amplification of PBX1 in leukemia-derived cell lines and in healthy controls separated into
2% agarose gels and visualized under UV light (upper panel). Genome map of complete (a) and alternative (b) splicing of PBX1; C) Sequence of
alternative splicing of PBX1 showing adjacent coding regions of the deleted exon.
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Page 3 of 12calculate ΔCP values. As can be observed in Figure 3,
distribution of ΔCPs obtained for ALL samples were
noticeably different from those obtained for control
samples in the cases of MEIS1 and PREP1. Differences
in ΔCP values for MEIS2 and PREP2 in patients com-
pared with controls were not statistically significant. For
the PBX group (see Figure 4), we observed that PBX1
and PBX3 were, to some extent, up-regulated in patients
with ALL, but this difference was only statistically signif-
icant when we normalized with reference gene RPL32.
PBX2 expression remained unchanged in patients and
controls, and the sole member that clearly exhibited
down-regulation in ALL samples was PBX4.
MEIS1 Silencing Decreases the Proliferation Rate of
Leukemic-derived Cell Lines
Because we determined a consistent up-regulation of
MEIS1 and PREP1 in cell lines and in samples of
patients with ALL, it was interesting to us to determine
which type of advantage provides the high expression of
these genes to leukemic cells. First we analyzed the role
of MEIS1.T h eMEIS1 gene has been localized in chro-
mosome 2 and it has been described that Jurkat cells
are monosomic for this chromosome, CEM cells have
two copies, and K562 cells are trisomic [21]; in this
regard, expression of MEIS1 ought to be different in
these cell lines. To test this hypothesis, we analyzed
MEIS1 baseline expression in these cell lines by qRT-
Figure 2 Baseline expression level of Three-amino-acid loop-extension (TALE) family genes (MEIS1, MEIS2, PREP1, PREP2, PBX1, PBX2,
PBX3, and PBX4) in healthy cells vs. leukemia-derived cell lines. The graphics-display means and Standard deviation (SD) of ΔCP values
obtained for the expression level of TALE genes. Values were calculated taking RPL32 or ACTB as reference genes. The squares and diamonds
represent means ± SD of two independent experiments.
Table 2 Overview of controls and patients
Control
ID
Gender Age
(years)
Patient
ID
Gender Age
(years)
Diagnosis
1 M 33 1 M 38 ALL
2 M 26 2 M 82 ALL
3 F 54 3 M 56 ALL
4 F 34 4 F 46 ALL
5 F 68 5 F 32 ALL
6 M 51 6 F 36 ALL
7 F 43 7 F 56 ALL
8 F 24 8 M 84 ALL
9 F 56 9 M 61 ALL
10 M 40 10 M 58 ALL
11 F 53 11 F 30 ALL
12 F 35 12 M 52 ALL
13 F 26 13 F 43 ALL
14 M 39 14 M 18 ALL
15 M7 3
16 M4 5
17 F3 9
18 M4 0
19 M2 6
ALL, Acute lymphoblastic leukemia; ID, identification; M, Masculine; F,
Feminine.
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Page 4 of 12PCR (Figure 5A). As expected, Jurkat was the cell line
with the lowest MEIS1 expression, followed by CEM
and K562 expressing highest levels. Taking advantage of
the existing different levels of MEIS1 in the cell lines,
we utilized Jurkat and K562 cells to investigate whether
high MEIS1 expression is related with increased prolif-
eration. We observed that K562 have a higher prolifera-
tion rate than Jurkat cells (Figure 5B). To demonstrate
the direct involvement of MEIS1 in this exacerbated
proliferation, we performed silencing assays in both cell
lines. We employed short hairpin RNAs shRNAs direc-
ted to two different regions of MEIS1 mRNA: one was
directed to Exon 9 (E9), and the other to Exon 13 (E13).
By using recombinant virus, we introduced these
sequences into Jurkat and K562 cells. To assure that all
infected cells were carrying the construction, a resis-
t a n c eg e n et op u r o m y c i nw a sa l s oi n t r o d u c e da n dt h e
infected cells were selected with this antibiotic.
Additionally, we infected the cells with an empty virus
(without shRNA) and selected them also with puromy-
c i ni no r d e rt op o s s e sac o n t r o lf o rt h es e l e c t i o na n d
infection process. We then tested MEIS1 (mRNA) levels
by qRT-PCR. As shown in Figures 5C and 5E, MEIS1
m R N Al e v e l sd e c r e a s ew i t hb o t hs h R N A si nb o t hc e l l
lines to nearly 50% of the initial expression. Employing
the MEIS1-silenced cells, we then measured the prolif-
eration rate and observed that proliferation was affected
in all clones in which MEIS1 was silenced (Figures 5D
and 5F). This effect was more obvious in K562 cells,
which are the cells that express more MEIS1.
Expression of MEIS1 and PREP1 Is Modulated in Response
to Apoptosis Induction by Etoposide
The other TALE member that we found up-regulated in
leukemic cells was PREP1. Expression of this gene has
been associated with resistance to apoptosis and it also
Figure 3 Levels of MEIS1-2 and PREP1-2 in healthy volunteers vs. patients with leukemia. Box plot graphics showing ΔCP values taking
ACTB (left panel) or RPL32 (right panel) as reference genes. The graphics display median (dark lines), 25‒75
th percentile (boxes), interquartile
ranges (whiskers), and outliers (*) from the 14 patients with Acute lymphoblastic leukemia (ALL) and the 19 controls (C). Unpaired Student t test
was used to compare ALL with Control group. Statistical significances are shown between groups only when p ≤ 0.05.
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Page 5 of 12has been described that PREP1 regulates MEIS1 expres-
sion [20,22]. In this respect, we subsequently analyzed
whether the expression of PREP1 and MEIS1 was
related with resistance to apoptosis induction by che-
motherapeutic stimulus in leukemic cells. In order to
assess this parameter, cultured cells were exposed to
etoposide for 1 or 2 h; thereafter, variations in MEIS1
and PREP1 expression were analyzed by qRT-PCR. We
observed that after etoposide treatment, Jurkat cells
exhibit a tendency to increase MEIS1 expression, CEM
cells remained unchanged, while diminishes K562
expression was noteworthy (Figure 6A). For PREP1,
nearly no difference was observed in Jurkat cells; the
response of CEM cells was more important because a
notorious up-regulation was evidenced. Interestingly,
K562 cells down-regulate PREP1 expression in
response to etoposide (Figure 6A). To correlate these
observations with phenotypic response, we measured
the percentage of apoptotic cells after 5, 15, and 24 h
of etoposide treatment. As can be observed in Figure
6B, Jurkat cells were the cells most sensitive to etopo-
side action; in contrast, CEM and K562 cells were the
most resistant cells.
Given that K562 cells show a chemotherapeutic-resis-
tant phenotype and that response of these cells to eto-
poside exposure is the down-modulation of MEIS1,a n d
because we observed that Jurkat cells increased MEIS1
expression and were the most sensitive cells, we postu-
late that MEIS1 down-regulation could be a mechanism
for resistance to etoposide-induced apoptosis. In this
regard, Jurkat clones with MEIS1-silenced should be
more resistant than Jurkat infected with the empty virus
(pLVX) or with parental Jurkat cells. We tested this
hypothesis exposing the cells to etoposide and measur-
ing the percentage of surviving cells (Figure 6C). From
this approach, we observed that Jurkat clones in which
MEIS1 was silenced demonstrated a higher percentage
of cell survival compared with pLVX infected cells or
Figure 4 Levels of PBX1-4 in healthy volunteers vs. patients with leukemia. Box plot graphics showing ΔCP values taking ACTB (left panel)
or RPL32 (right panel) as reference genes. The graphics display median (dark lines), 25‒75
th percentile (boxes), interquartile ranges (whiskers), and
outliers (*) from the 14 patients with Acute lymphoblastic leukemia (ALL) and the 19 controls (C). Unpaired Student t test was used to compare
ALL with Control group. Statistical significances are shown between groups only when p ≤ 0.05
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Page 6 of 12Figure 5 Effect of MEIS1 expression on cell growth of leukemia-derived cell lines. A) Expression levels of MEIS1 were analyzed by qRT-PCR
in Jurkat, CEM, and K562 cells; expression of RPL32 was also determined and used as reference gene to calculate relative expression; B) Cell
proliferation analysis of K562 and Jurkat cells; C, E) Expression levels of MEIS1 in Jurkat and K562 cell lines infected with virus carrying shRNA-E9
or shRNA-E13. Values were obtained by qRT-PCR using RPL32 as reference gene; D, F) Proliferation of MEIS1-silenced cells. Jurkat and K562 cells
were infected with an shRNA directed to exon 9 (LVX-E9) and an shRNA directed to exon 13 (LVX-E13). Cell growth was determined counting
the cells daily for 5 days. Graphics show means ± Standard deviations (SD) of values obtained from three independent experiments. Statistical
differences were calculated at the end point of proliferation curves using 2 way ANOVA analysis and Bonferroni posttest, (*) significances are
shown between groups only when p ≤ 0.05.
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Page 7 of 12Figure 6 Modulation of MEIS1 and PREP1 expression after etoposide treatment. A) Jurkat, CEM, and K562 cells were treated with 170 μM
etoposide for 1 and 2 h; thereafter, total RNA was extracted and retrotranscribed. Real time-PCR assays were performed to determine the
relative expression levels of MEIS1 and PREP1. Expression analysis was carried out by normalizing with non-treated cells and employing RPL32 as
reference gene. The bars represent means ± Standard deviations (SD) of two independent experiments; B) Percentage of apoptotic cells induced
by etoposide treatment. Jurkat, CEM, and K562 cells were treated with 170 μM etoposide; the percentage of apoptotic cells was measured using
Annexin-V-FLUOS. The bars represent means ± Standard deviations (SD) of three independent experiments. C) MEIS1-silenced (LVX-E9 and -E13)
cells were treated with 170 μM etoposide for 12 and 24 hours. Parental cells (Jurkat and K562) or empty vector-silenced cells (LVX) were also
used. After etoposide treatment WST-1 was added to cell cultures and incubate for 3 additional hours. The percentage of cell survival was
calculated measuring Optical density (OD) at 450 nm (OD of untreated cells was set as 100%). Statistical differences were calculated at the end
point of the curves using 2 way ANOVA analysis and Bonferroni posttest, (*) significances are shown between groups only when p ≤ 0.05.
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Page 8 of 12parental cells. MEIS1 silencing in K562 cells did not
further increased the percentage of surviving cells.
Discussion
TALE genes are a particular group of homeobox genes
that are important in the regulation of proliferation,
apoptosis, and normal cell differentiation. Anomalous
expression of these genes has been involved in the
development of hematological malignancies [23]. In this
work, we first analyzed variations in the expression of
TALE genes in leukemia-derived cell lines compared
with normal control cells. In that we observed dissimilar
MEIS1, MEIS2,a n dPREP1 expression levels, we wished
to confirm whether these changes were also observed in
samples of patients with leukemia. Interestingly, we
found variations in MEIS1, PREP1,a n dPBX4 expres-
sion. It has been reported that over-expression of
MEIS1 blocks myeloid cell differentiation; thus, high
levels of MEIS1 are required to maintain hematopoietic
cells in an undifferentiated state [13]. We observed high
levels of MEIS1 mRNA in leukemia-derived cell lines
and also in the blood samples of patients with ALL; our
results are in agreement with observations that lower
levels of MEIS1 are unfavorable for cell life, because
MEIS1 down-regulation has been related with decreased
proliferation and poor survival of neuroblastoma and
leukemia cell lines [24,25]. Moreover, Kawagoe et al.
reported that down-regulation of MEIS1 is required to
induce differentiation of hematopoietic cells [26]. Our
f i n d i n g ss u p p o r tt h en o t i o nt h a tt h i sg e n ep l a y sa n
oncogenic role and that its expression is required to sus-
tain proliferation and block differentiation in leukemia
cells [24,27]. Controversially, it has been reported that
high levels of this protein can also trigger apoptosis; we
observed that high MEIS1-expressing K562 cells were
more resistant to apoptosis induction than Jurkat cells,
which exhibited lower levels of MEIS1;h o w e v e r ,i ti s
also well known that MEIS1 requires the presence of
protein partners to achieve its different functions
[16,28,29]; one explanation for the contradictory effects
reported for MEIS1 could be that, regardless of higher
MEIS1 expression, cells can regulate the action of this
protein by modulating the expression of MEIS1 cofac-
tors, such as HOX. The availability of the later can
transform MEIS1 action from proliferative into pro-
apoptotic [28].
In the cell lines studied, we observed that an apoptotic
stimulus induces MEIS1 up- and down-regulation (Jur-
kat and K562, respectively). A strategy of tumor cells for
survival could be down-regulation of MEIS1. In this
respect, through lowering its proliferation rate, tumor
cells avoid DNA damage, which can induce apoptosis.
Regarding MEIS2 expression, this gene has been found
in immature neuronal precursor cells, lens proliferative
cells, ovarian cancer, and other tumor cell types, which
underlies its possible role in sustaining proliferation
[30]. We observed strong expression in leukemia-derived
cell lines compared with control cells, which is in agree-
ment with the findings of Smith et al. [31]; however,
when we analyzed its expression in patients, we found
no variation in the expression of this gene (Figure 3).
To a greater extent, we observed that all studied cell
lines express PREP1,b u tn o tPREP2. PREP1 has been
described to be ubiquitously expressed in adult tissues
[32] and PREP2 is depicted as possessing more
restricted expression, being negative in peripheral blood
leukocytes [2]. After apoptosis induction by etoposide,
CEM cells greatly increase PREP1 gene expression,
PREP1 has been directly involved in the regulation of
apoptosis: it has been described that BCLXL, an intrinsic
apoptotic-pathway regulator, is a direct target of PREP1
[22]. PREP proteins interact with PBX members to
achieve their functions [33]. Interaction of PREP with
PBX1 and PBX2 increases the stability of PBX proteins
and additionally increases the affinity of PREP for DNA
binding [34,35]; the expression of BCLXL and p53 has
been reported to be regulated by PREP1 in cooperation
with PBX1b [22,36]. In etoposide-treated CEM cells, it
w a so b s e r v e dt h a te x p r e s s i o no fPBX2 and PBX4
increases (Additional file 1); PBX2 has been reported as
a negative apoptosis modulator through negative regula-
tion of BCL2 [37]. Up-regulation of PREP1 together
with down-regulation of PBX genes could account for
the etoposide-resistant phenotype of CEM cells; this
resistance could be mediated by BCLXL and p53. High
levels of p53 have been associated with apoptosis but, in
t h ep r e s e n c eo fB C L XL-mediated survival signals, p53
can induce senescence instead of apoptosis [38].
Conclusions
In conclusion, our study shows that MEIS1 and PREP1
mRNA levels are significantly up-regulated in patients
w i t hA L Li nc o m p a r i s o nw i t hh e a l t h yc o n t r o l sa n d
inversely, that PBX4 is down-regulated in patients with
ALL. Importantly, utilizing silencing assays, we con-
firmed that down-modulation of MEIS1 produces a
lower leukemic-cell proliferation rate, an effect that was
most notorious in the K562 myeloblastic cell line. Eto-
poside- induced apoptosis leads to changes in the
expression of PREP1 and MEIS1; up-regulation of
PREP1 and down-regulation of MEIS1 were indepen-
dently related with resistance to apoptosis. Taken
together, these results support the important role that
TALE genes play in leukemic cell proliferation and sur-
vival, in addition to their probable involvement during
leukemia development. Therefore, it could be important
to evaluate MEIS1 and PREP1 expression in patients
with leukemia prior to and after chemotherapeutic
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Page 9 of 12treatment and to correlate these findings with the clini-
cal response.
Methods
Cells and cell culture
We used five commercially available human leukemia-
derived cell lines: MOLT-4; Jurkat and CEM cells
derived from lymphoid leukemia; HL-60 derived from
promyelocytic leukemia, and K562 from erythroleuke-
mia. Cells were grown in RPMI-1640 medium supple-
mented with 10% Fetal bovine serum (FBS), penicillin
(100 U/mL,) and streptomycin (100 μg/mL); all products
mentioned previously were obtained from GIBCO™
(Invitrogen Corp., Carlsbad, CA, USA). Cultures were
maintained at 37°C in a humidified atmosphere with 5%
CO2.
Patients and sample collection
Peripheral blood samples were collected from 14
patients with Acute lymphoblastic leukemia (ALL)
according to World Health Organization (WHO) classi-
fication criteria at the Centro Médico Nacional de Occi-
dente of the Mexican Social Security Institute (CIBO-
IMSS) and the Hospital Civil de Guadalajara Fray Anto-
nio Alcalde. Additionally, blood samples from 19 healthy
donors were also collected from the IMSS Blood Bank.
Letters of informed consent and protocols were
approved by the CLIS-1305 Ethical Board of CIBO-
IMSS.
Drugs and in vitro cell treatments
Etoposide was obtained from Lemery Laboratorios,
México. The drug was stored at 4°C for <4 days and
adjusted to the desirable concentration with DMEM cul-
ture medium immediately prior to utilization. The con-
centration employed was 170 μM etoposide.
RNA extraction and cDNA synthesis
Total RNA was isolated by using the PureLink™ Micro-
to-Midi Total RNA Purification System (Invitrogen
Corp.) from 5 × 10
6 cultured cells as described by the
manufacturer. Peripheral blood samples from patients
with leukemia and from healthy donors were collected
with EDTA as anticoagulant and mixed immediately
after collection with 45 mL of RNA/DNA Stabilization
Reagent for Blood/Bone Marrow (Roche Applied
Science, Germany) and stored at ‒80°C for preservation.
The stabilized samples were utilized for mRNA isolation
via a two-step procedure by means of magnetic separa-
tion employing the mRNA Isolation kit for blood/bone
marrow (Roche Applied Science). mRNA was finally
eluted from the magnetic pearls in 20 μL of water and
stored at ‒80°C until use.
cDNA synthesis was performed from 5 μgo ft o t a l
RNA or 12 uL mRNA employing the Transcriptor First
Strand cDNA Synthesis kit primed with oligo(dT) (cat.
no. 04897030001, Roche Applied Science). The protocol
was conducted as recommended by the manufacturer.
cDNA were stored at ‒20°C and aliquots were utilized
as templates for PCR and RT-PCR reactions.
PCR and RT-PCR
PCR reactions were carried out utilizing the set of pri-
mers presented in Table 1; the primers were designed
using Oligo v6.0 software from sequences obtained from
the NCBI-website GenBank Nucleotide database. PCR
was performed using Taq DNA Polymerase (cat. no.
11146173001, Roche Applied Science) and Deoxynucleo-
side triphosphates (cat. no. 1969064, Roche Applied
Science) in a PX2 Thermal Cycler (Thermo Electron
Corp.). All reactions were conducted in 20 μLa tt h e
specified Tm (see Table 1). PCR products were resolved
in 2% agarose gels containing 0.1 μg/mL ethidium bro-
mide (Sigma Aldrich, Germany), visualized under Ultra-
violet (UV) light, and documented with a DigiDoc-It
System, (UVP, UK). RT-PCR analysis was achieved by
employing the LightCycler-FastStart DNA MasterPLUS
SYBR Green I kit (cat. no. 03515885001, Roche Applied
Science) in the LightCycler 1.5 System (Roche Diagnos-
tics GmbH, Mannheim, Germany). Data were normal-
ized to the expression of the reference genes RPL32
(L32 Ribosomal Protein) and ACTB (b-actin).
ΔCP analysis
To normalize target gene expression, we employed two
different reference genes. We calculated the Crossing
point (CP) for target and reference genes in each sample
and subsequently calculated the ΔCP value of each sam-
ple, i.e., the target gene CP minus the reference gene
CP. This facilitated analysis by taking only the intrinsic
values of each sample. CPs from ACTB,a n dRLP32
were employed for this analysis. It is extremely note-
worthy that ΔCP is inversely proportional to the expres-
sion of the target gene.
Lentivirus production and infection
Oligonucleotides used to construct shRNAs were: for-
ward 5’- GAT CCG CGG GAC TCA CCA TCC TTC
AAG TGA ATT CAA GAG ATT CAC TTG AAG
GAT GGT GAG TCC CGT TTT TTG-3’ and reverse
5’-AAT TCA AAA AAC GGG ACT CAC CAT CCT
TCA AGT GAA TCT CTT GAA TTC ACT TGA AGG
ATG GTG AGT CCC GCG-3’ directed to MEIS1 exon
9( E 9 ) ;f o r w a r d5 ’-GAT CCG CCG TGT GTT TAG
AAG CCT AAT TCA AGA GAT TAG GCT TCT AAA
CAC ACG GCT TTT TTA CGC GTG-3 and reverse 5’-
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AAG CCT AAT CTC TTG AAT TAG GCT TCT AAA
CAC ACG GCG-3’ directed to MEIS1 exon 13 (E13);
this latter sequence has been previously used [24]. Com-
plementary primers were annealed and cloned into the
vector pLVX-shRNA1 (Clontech Laboratories, USA)
using the restriction sites BamHI and EcoRI (NEB-Bio-
labs, USA). To produce infectious viral particles, Lenti-
X 293T cells were transient-transfected by Lentiphos
HT/Lenti-X HT Packaging Systems with lentiviral vec-
tors pLVX-Puro or pLVX-shRNA1-E9 or pLVX-
shRNA1-E13 as described by the manufacturer (Clon-
tech Laboratories, USA). After 48 h, supernatants were
checked with Lenti-X GoStix (Clontech Laboratories,
USA) to determine whether sufficient viral particles
were produced before transducing target cells. Superna-
tants were filtered through a 0.22-μm PES filter to elimi-
nate detached cells, were aliquoted, and subsequently
stored at ‒80°C until use. Jurkat and K562 cells (2.5 ×
10
5) were transduced with approximately 4.5 × 10
5 IFU/
mL of supernatants. RNA extractions were obtained
after at least 2 weeks of puromycin selection (1 μg/mL).
Cell survival determination
Cell survival was determined by cleavage of tetrazolium
salt WST-1 to formazan by cellular mitochondrial dehy-
drogenase enzymes. After different treatment periods,
cells were incubated with 10 μL/well of WST-1/ECS
solution (BioVision Research, Mountain View, CA,
USA) for 3 h. Absorbance (450 nm) of treated and
untreated samples was determined on a microtiter plate
reader (Synergy™ HT Multi-Mode Microplate Reader;
Biotek, Winooski, VT, USA). Data are reported as per-
centage of cell survival taking untreated control cells as
100% of cell survival.
Apoptosis detection
Cell death was measured by flow cytometry using propi-
dium iodide (cat. no. P4864, Sigma-Aldrich) and
Annexin-V-FlUOS (cat. no. 1828681, Roche Applied
Science) as recommended by these manufacturers. Cells
were seeded in 6-well plates at a density of 3 × 10
5 cells
per well in 1 mL RPMI medium containing or not eto-
poside (170 μM). After 5, 15, and 25 h, each sample was
analyzed in a FACS Aria cytometer (BD Biosciences).
Additional material
Additional file 1: Modulation of PBX1-4 expression after etoposide
treatment. Jurkat and CEM cells were treated with 170 μM etoposide for
1 and 2 h; thereafter, total RNA was extracted and retrotranscribed. Real
time-PCR assays were performed to determine the relative expression
levels of PBX1-4. Expression analysis was carried out by normalizing with
non-treated cells and employing RPL32 as reference gene. The bars
represent means ± Standard deviations (SD) of two independent
experiments.
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